English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 April 2020, 16:00 HKT/SGT

Source: Avance Clinical
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials

ADELAIDE, AUS, Apr 2, 2020 - (ACN Newswire) - Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. Avance is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise.

Avance Clinical said a primary reason that APAC biotechs chose Australia was the attractive Australian Government financial rebate of more than 40% on clinical trial spend. Avance Clinical CEO Yvonne Lungershausen said this makes good financial sense for biotechs in early clinical phases.

Another key factor is that, during the current COVID-19 pandemic, sites can pivot to patient video visits or telemedicine, which this week got a Government funding boost as part of a AUD$1.1 billion COVID-19 package.

Watch Avance Clinical COVID-19 capabilities video here: https://www.avancecro.com/

Ms Lungershausen said:

"This additional funding into an already high-tech medical environment means sites are rapidly able to incorporate telehealth visits to overcome challenges faced by patients not wanting to visit clinics during the pandemic."

"Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials."

"Avance is the CRO of choice for clinical trials - as well as those targeting COVID-19."

The top reasons for selecting Australia are:
1. The Government R&D grant means more than 40% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialised patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

- Access to independent Phase 1 facilities across Australia including hospital-based units for critical care
- Dedicated Investigators committed to clinical research
- Major hospitals with world class infrastructures and dedicated Clinical Trial Units
- Expedited clinical trial start-up timeframes

Media Contact:
Chris Thompson

Topic: Clinical Trial Results
Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Avance Clinical Related News
Oct 19, 2023 18:00 HKT/SGT
아방스 클리니컬, 45개의 한국 생명 공학 기업 초청해 한국과 호주에서 미국으로 이어지는 글로벌레디 신약 개발 경로에 대한 설명회 개최
2023年10月19日 12時00分 JST
Oct 19, 2023 09:00 HKT/SGT
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
2023年5月30日 20時00分 JST
アバンセ・クリニカルがASCO & BIO 2023に参加 初期段階のオンコロジー試験はより精緻化、より多くの患者を必要とする
May 30, 2023 11:00 HKT/SGT
2023 ASCO和BIO上的Avance Clinical:早期肿瘤治疗试验越来越复杂,对患者的需求也越来越大
More news >>
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575